Global Osteonecrosis Market

Osteonecrosis Comprehensive Study by Application (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers), Diagnoses Used (X-Ray, MRI, Bone Scans, Ct Scan, Surgical Procedures), Route of Administration (Oral, Parenteral), Treatment Type (Conservative Treatment (Medication, Reduced Weight Bearing, Range of Motion Exercises, Electrical Stimulation), Surgical Treatment (Core Decompression, Osteotomy, Arthroplasty)) Players and Region - Global Market Outlook to 2025

Osteonecrosis Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Osteonecrosis Market Overview:
Osteonecrosis is a disorder causing a temporary or permanent loss of blood supply to the bone. When the blood supply is interrupted, the bone tissues (osteo) begin to break down (necrosis) it weakens the bone and ultimately results in its collapse. If this occurs near a joint, it can lead to the collapse of the joint surface, resulting in pain and swelling (arthritis). Osteonecrosis is also denoted as avascular necrosis (AVN), aseptic necrosis, and ischemic bone necrosis. Osteonecrosis can occur in any bone, but most usually affect the ends of long bones such as the thigh bone, causing hip and knee problems. Other common sites comprise the bones of the shoulders, upper arms, and ankles, more commonly occurs in several bones at one time.

Market Drivers
  • Rising Demand for Non-Invasive Treatment
  • Up surging Dependence on Surgery to Cure Osteonecrosis

Market Trend
  • Rising Healthcare Burden of Osteonecrosis among Different Age Groups
  • Increasing Hip Injuries

Restraints
  • High Cost of Available For Osteonecrosis Treatments

Opportunities
  • Rising Awareness Regarding Non-Invasive Method of Osteonecrosis Treatment

Challenges
  • Adverse Side Effects Associated With Osteonecrosis Treatment Is Hampering the Market Growth
  • Lack of Skilled Professionals In This Field


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Bone Therapeutics SA (Belgium), Enzo Biochem Inc. (United States), Atnahs (United Kingdom), Teva Pharmaceutical Industries (Israel), Merck & Co. Inc. (United States), Novartis AG (Switzerland), Pfizer Inc. (United States), Johnson & Johnson Services, Inc. (United States), Mylan N.V (United States), Amgen Inc. (United States), Zimmer Biomet (United States) and Micromedic Technologies Ltd. (Israel). Additionally, following companies can also be profiled that are part of our coverage like Exactech, Inc. (United States), Medacta International (Switzerland) and Vericel Corporation (United States). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Osteonecrosis market by 2025. Considering Market by Diagnoses Used, the sub-segment i.e. X-Ray will boost the Osteonecrosis market. Considering Market by Route of Administration, the sub-segment i.e. Oral will boost the Osteonecrosis market. Considering Market by Treatment Type, the sub-segment i.e. Conservative Treatment [Medication, Reduced Weight Bearing, Range of Motion Exercises, Electrical Stimulation] will boost the Osteonecrosis market.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Osteonecrosis market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Osteonecrosis market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Osteonecrosis Drug, Suppliers of Osteonecrosis Drug, Wholesalers, Distributors and Retailers of Osteonecrosis Drug, Healthcare Industry, Osteonecrosis Treatment Service Providers and Governmental Bodies.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Orthopedic Clinics
  • Ambulatory Surgical Centers
By Diagnoses Used
  • X-Ray
  • MRI
  • Bone Scans
  • Ct Scan
  • Surgical Procedures

By Route of Administration
  • Oral
  • Parenteral

By Treatment Type
  • Conservative Treatment [Medication, Reduced Weight Bearing, Range of Motion Exercises, Electrical Stimulation]
  • Surgical Treatment [Core Decompression, Osteotomy, Arthroplasty]

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Demand for Non-Invasive Treatment
      • 3.2.2. Up surging Dependence on Surgery to Cure Osteonecrosis
    • 3.3. Market Challenges
      • 3.3.1. Adverse Side Effects Associated With Osteonecrosis Treatment Is Hampering the Market Growth
      • 3.3.2. Lack of Skilled Professionals In This Field
    • 3.4. Market Trends
      • 3.4.1. Rising Healthcare Burden of Osteonecrosis among Different Age Groups
      • 3.4.2. Increasing Hip Injuries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Osteonecrosis, by Application, Diagnoses Used, Route of Administration, Treatment Type and Region (value and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Osteonecrosis (Value)
      • 5.2.1. Global Osteonecrosis by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Orthopedic Clinics
        • 5.2.1.3. Ambulatory Surgical Centers
      • 5.2.2. Global Osteonecrosis by: Diagnoses Used (Value)
        • 5.2.2.1. X-Ray
        • 5.2.2.2. MRI
        • 5.2.2.3. Bone Scans
        • 5.2.2.4. Ct Scan
        • 5.2.2.5. Surgical Procedures
      • 5.2.3. Global Osteonecrosis by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Parenteral
      • 5.2.4. Global Osteonecrosis by: Treatment Type (Value)
        • 5.2.4.1. Conservative Treatment [Medication, Reduced Weight Bearing, Range of Motion Exercises, Electrical Stimulation]
        • 5.2.4.2. Surgical Treatment [Core Decompression, Osteotomy, Arthroplasty]
      • 5.2.5. Global Osteonecrosis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Osteonecrosis (Price)
  • 6. Osteonecrosis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bone Therapeutics SA (Belgium)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Enzo Biochem Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Atnahs (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceutical Industries (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co. Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johnson & Johnson Services, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Mylan N.V (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Amgen Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Zimmer Biomet (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Micromedic Technologies Ltd. (Israel)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Osteonecrosis Sale, by Application, Diagnoses Used, Route of Administration, Treatment Type and Region (value and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Osteonecrosis (Value)
      • 7.2.1. Global Osteonecrosis by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Orthopedic Clinics
        • 7.2.1.3. Ambulatory Surgical Centers
      • 7.2.2. Global Osteonecrosis by: Diagnoses Used (Value)
        • 7.2.2.1. X-Ray
        • 7.2.2.2. MRI
        • 7.2.2.3. Bone Scans
        • 7.2.2.4. Ct Scan
        • 7.2.2.5. Surgical Procedures
      • 7.2.3. Global Osteonecrosis by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Parenteral
      • 7.2.4. Global Osteonecrosis by: Treatment Type (Value)
        • 7.2.4.1. Conservative Treatment [Medication, Reduced Weight Bearing, Range of Motion Exercises, Electrical Stimulation]
        • 7.2.4.2. Surgical Treatment [Core Decompression, Osteotomy, Arthroplasty]
      • 7.2.5. Global Osteonecrosis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Osteonecrosis (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Osteonecrosis: by Application(USD Million)
  • Table 2. Osteonecrosis Hospitals , by Region USD Million (2014-2019)
  • Table 3. Osteonecrosis Orthopedic Clinics , by Region USD Million (2014-2019)
  • Table 4. Osteonecrosis Ambulatory Surgical Centers , by Region USD Million (2014-2019)
  • Table 5. Osteonecrosis: by Diagnoses Used(USD Million)
  • Table 6. Osteonecrosis X-Ray , by Region USD Million (2014-2019)
  • Table 7. Osteonecrosis MRI , by Region USD Million (2014-2019)
  • Table 8. Osteonecrosis Bone Scans , by Region USD Million (2014-2019)
  • Table 9. Osteonecrosis Ct Scan , by Region USD Million (2014-2019)
  • Table 10. Osteonecrosis Surgical Procedures , by Region USD Million (2014-2019)
  • Table 11. Osteonecrosis: by Route of Administration(USD Million)
  • Table 12. Osteonecrosis Oral , by Region USD Million (2014-2019)
  • Table 13. Osteonecrosis Parenteral , by Region USD Million (2014-2019)
  • Table 14. Osteonecrosis: by Treatment Type(USD Million)
  • Table 15. Osteonecrosis Conservative Treatment [Medication, Reduced Weight Bearing, Range of Motion Exercises, Electrical Stimulation] , by Region USD Million (2014-2019)
  • Table 16. Osteonecrosis Surgical Treatment [Core Decompression, Osteotomy, Arthroplasty] , by Region USD Million (2014-2019)
  • Table 17. South America Osteonecrosis, by Country USD Million (2014-2019)
  • Table 18. South America Osteonecrosis, by Application USD Million (2014-2019)
  • Table 19. South America Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 20. South America Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 21. South America Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 22. Brazil Osteonecrosis, by Application USD Million (2014-2019)
  • Table 23. Brazil Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 24. Brazil Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 25. Brazil Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 26. Argentina Osteonecrosis, by Application USD Million (2014-2019)
  • Table 27. Argentina Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 28. Argentina Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 29. Argentina Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 30. Rest of South America Osteonecrosis, by Application USD Million (2014-2019)
  • Table 31. Rest of South America Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 32. Rest of South America Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 33. Rest of South America Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 34. Asia Pacific Osteonecrosis, by Country USD Million (2014-2019)
  • Table 35. Asia Pacific Osteonecrosis, by Application USD Million (2014-2019)
  • Table 36. Asia Pacific Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 37. Asia Pacific Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 38. Asia Pacific Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 39. China Osteonecrosis, by Application USD Million (2014-2019)
  • Table 40. China Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 41. China Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 42. China Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 43. Japan Osteonecrosis, by Application USD Million (2014-2019)
  • Table 44. Japan Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 45. Japan Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 46. Japan Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 47. India Osteonecrosis, by Application USD Million (2014-2019)
  • Table 48. India Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 49. India Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 50. India Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 51. South Korea Osteonecrosis, by Application USD Million (2014-2019)
  • Table 52. South Korea Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 53. South Korea Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 54. South Korea Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 55. Taiwan Osteonecrosis, by Application USD Million (2014-2019)
  • Table 56. Taiwan Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 57. Taiwan Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 58. Taiwan Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 59. Australia Osteonecrosis, by Application USD Million (2014-2019)
  • Table 60. Australia Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 61. Australia Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 62. Australia Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 63. Rest of Asia-Pacific Osteonecrosis, by Application USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 67. Europe Osteonecrosis, by Country USD Million (2014-2019)
  • Table 68. Europe Osteonecrosis, by Application USD Million (2014-2019)
  • Table 69. Europe Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 70. Europe Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 71. Europe Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 72. Germany Osteonecrosis, by Application USD Million (2014-2019)
  • Table 73. Germany Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 74. Germany Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 75. Germany Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 76. France Osteonecrosis, by Application USD Million (2014-2019)
  • Table 77. France Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 78. France Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 79. France Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 80. Italy Osteonecrosis, by Application USD Million (2014-2019)
  • Table 81. Italy Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 82. Italy Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 83. Italy Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 84. United Kingdom Osteonecrosis, by Application USD Million (2014-2019)
  • Table 85. United Kingdom Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 86. United Kingdom Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 87. United Kingdom Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 88. Netherlands Osteonecrosis, by Application USD Million (2014-2019)
  • Table 89. Netherlands Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 90. Netherlands Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 91. Netherlands Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 92. Rest of Europe Osteonecrosis, by Application USD Million (2014-2019)
  • Table 93. Rest of Europe Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 94. Rest of Europe Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 95. Rest of Europe Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 96. MEA Osteonecrosis, by Country USD Million (2014-2019)
  • Table 97. MEA Osteonecrosis, by Application USD Million (2014-2019)
  • Table 98. MEA Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 99. MEA Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 100. MEA Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 101. Middle East Osteonecrosis, by Application USD Million (2014-2019)
  • Table 102. Middle East Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 103. Middle East Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 104. Middle East Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 105. Africa Osteonecrosis, by Application USD Million (2014-2019)
  • Table 106. Africa Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 107. Africa Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 108. Africa Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 109. North America Osteonecrosis, by Country USD Million (2014-2019)
  • Table 110. North America Osteonecrosis, by Application USD Million (2014-2019)
  • Table 111. North America Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 112. North America Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 113. North America Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 114. United States Osteonecrosis, by Application USD Million (2014-2019)
  • Table 115. United States Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 116. United States Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 117. United States Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 118. Canada Osteonecrosis, by Application USD Million (2014-2019)
  • Table 119. Canada Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 120. Canada Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 121. Canada Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 122. Mexico Osteonecrosis, by Application USD Million (2014-2019)
  • Table 123. Mexico Osteonecrosis, by Diagnoses Used USD Million (2014-2019)
  • Table 124. Mexico Osteonecrosis, by Route of Administration USD Million (2014-2019)
  • Table 125. Mexico Osteonecrosis, by Treatment Type USD Million (2014-2019)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Osteonecrosis: by Application(USD Million)
  • Table 139. Osteonecrosis Hospitals , by Region USD Million (2020-2025)
  • Table 140. Osteonecrosis Orthopedic Clinics , by Region USD Million (2020-2025)
  • Table 141. Osteonecrosis Ambulatory Surgical Centers , by Region USD Million (2020-2025)
  • Table 142. Osteonecrosis: by Diagnoses Used(USD Million)
  • Table 143. Osteonecrosis X-Ray , by Region USD Million (2020-2025)
  • Table 144. Osteonecrosis MRI , by Region USD Million (2020-2025)
  • Table 145. Osteonecrosis Bone Scans , by Region USD Million (2020-2025)
  • Table 146. Osteonecrosis Ct Scan , by Region USD Million (2020-2025)
  • Table 147. Osteonecrosis Surgical Procedures , by Region USD Million (2020-2025)
  • Table 148. Osteonecrosis: by Route of Administration(USD Million)
  • Table 149. Osteonecrosis Oral , by Region USD Million (2020-2025)
  • Table 150. Osteonecrosis Parenteral , by Region USD Million (2020-2025)
  • Table 151. Osteonecrosis: by Treatment Type(USD Million)
  • Table 152. Osteonecrosis Conservative Treatment [Medication, Reduced Weight Bearing, Range of Motion Exercises, Electrical Stimulation] , by Region USD Million (2020-2025)
  • Table 153. Osteonecrosis Surgical Treatment [Core Decompression, Osteotomy, Arthroplasty] , by Region USD Million (2020-2025)
  • Table 154. South America Osteonecrosis, by Country USD Million (2020-2025)
  • Table 155. South America Osteonecrosis, by Application USD Million (2020-2025)
  • Table 156. South America Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 157. South America Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 158. South America Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 159. Brazil Osteonecrosis, by Application USD Million (2020-2025)
  • Table 160. Brazil Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 161. Brazil Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 162. Brazil Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 163. Argentina Osteonecrosis, by Application USD Million (2020-2025)
  • Table 164. Argentina Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 165. Argentina Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 166. Argentina Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 167. Rest of South America Osteonecrosis, by Application USD Million (2020-2025)
  • Table 168. Rest of South America Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 169. Rest of South America Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 170. Rest of South America Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 171. Asia Pacific Osteonecrosis, by Country USD Million (2020-2025)
  • Table 172. Asia Pacific Osteonecrosis, by Application USD Million (2020-2025)
  • Table 173. Asia Pacific Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 174. Asia Pacific Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 175. Asia Pacific Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 176. China Osteonecrosis, by Application USD Million (2020-2025)
  • Table 177. China Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 178. China Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 179. China Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 180. Japan Osteonecrosis, by Application USD Million (2020-2025)
  • Table 181. Japan Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 182. Japan Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 183. Japan Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 184. India Osteonecrosis, by Application USD Million (2020-2025)
  • Table 185. India Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 186. India Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 187. India Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 188. South Korea Osteonecrosis, by Application USD Million (2020-2025)
  • Table 189. South Korea Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 190. South Korea Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 191. South Korea Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 192. Taiwan Osteonecrosis, by Application USD Million (2020-2025)
  • Table 193. Taiwan Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 194. Taiwan Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 195. Taiwan Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 196. Australia Osteonecrosis, by Application USD Million (2020-2025)
  • Table 197. Australia Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 198. Australia Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 199. Australia Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 200. Rest of Asia-Pacific Osteonecrosis, by Application USD Million (2020-2025)
  • Table 201. Rest of Asia-Pacific Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 202. Rest of Asia-Pacific Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 203. Rest of Asia-Pacific Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 204. Europe Osteonecrosis, by Country USD Million (2020-2025)
  • Table 205. Europe Osteonecrosis, by Application USD Million (2020-2025)
  • Table 206. Europe Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 207. Europe Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 208. Europe Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 209. Germany Osteonecrosis, by Application USD Million (2020-2025)
  • Table 210. Germany Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 211. Germany Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 212. Germany Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 213. France Osteonecrosis, by Application USD Million (2020-2025)
  • Table 214. France Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 215. France Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 216. France Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 217. Italy Osteonecrosis, by Application USD Million (2020-2025)
  • Table 218. Italy Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 219. Italy Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 220. Italy Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 221. United Kingdom Osteonecrosis, by Application USD Million (2020-2025)
  • Table 222. United Kingdom Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 223. United Kingdom Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 224. United Kingdom Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 225. Netherlands Osteonecrosis, by Application USD Million (2020-2025)
  • Table 226. Netherlands Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 227. Netherlands Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 228. Netherlands Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 229. Rest of Europe Osteonecrosis, by Application USD Million (2020-2025)
  • Table 230. Rest of Europe Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 231. Rest of Europe Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 232. Rest of Europe Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 233. MEA Osteonecrosis, by Country USD Million (2020-2025)
  • Table 234. MEA Osteonecrosis, by Application USD Million (2020-2025)
  • Table 235. MEA Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 236. MEA Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 237. MEA Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 238. Middle East Osteonecrosis, by Application USD Million (2020-2025)
  • Table 239. Middle East Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 240. Middle East Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 241. Middle East Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 242. Africa Osteonecrosis, by Application USD Million (2020-2025)
  • Table 243. Africa Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 244. Africa Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 245. Africa Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 246. North America Osteonecrosis, by Country USD Million (2020-2025)
  • Table 247. North America Osteonecrosis, by Application USD Million (2020-2025)
  • Table 248. North America Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 249. North America Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 250. North America Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 251. United States Osteonecrosis, by Application USD Million (2020-2025)
  • Table 252. United States Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 253. United States Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 254. United States Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 255. Canada Osteonecrosis, by Application USD Million (2020-2025)
  • Table 256. Canada Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 257. Canada Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 258. Canada Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 259. Mexico Osteonecrosis, by Application USD Million (2020-2025)
  • Table 260. Mexico Osteonecrosis, by Diagnoses Used USD Million (2020-2025)
  • Table 261. Mexico Osteonecrosis, by Route of Administration USD Million (2020-2025)
  • Table 262. Mexico Osteonecrosis, by Treatment Type USD Million (2020-2025)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Osteonecrosis: by Application USD Million (2014-2019)
  • Figure 5. Global Osteonecrosis: by Diagnoses Used USD Million (2014-2019)
  • Figure 6. Global Osteonecrosis: by Route of Administration USD Million (2014-2019)
  • Figure 7. Global Osteonecrosis: by Treatment Type USD Million (2014-2019)
  • Figure 8. South America Osteonecrosis Share (%), by Country
  • Figure 9. Asia Pacific Osteonecrosis Share (%), by Country
  • Figure 10. Europe Osteonecrosis Share (%), by Country
  • Figure 11. MEA Osteonecrosis Share (%), by Country
  • Figure 12. North America Osteonecrosis Share (%), by Country
  • Figure 13. Global Osteonecrosis share by Players 2019 (%)
  • Figure 14. Global Osteonecrosis share by Players (Top 3) 2019(%)
  • Figure 15. Global Osteonecrosis share by Players (Top 5) 2019(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Bone Therapeutics SA (Belgium) Revenue, Net Income and Gross profit
  • Figure 18. Bone Therapeutics SA (Belgium) Revenue: by Geography 2019
  • Figure 19. Enzo Biochem Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Enzo Biochem Inc. (United States) Revenue: by Geography 2019
  • Figure 21. Atnahs (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Atnahs (United Kingdom) Revenue: by Geography 2019
  • Figure 23. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 24. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2019
  • Figure 25. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Merck & Co. Inc. (United States) Revenue: by Geography 2019
  • Figure 27. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Novartis AG (Switzerland) Revenue: by Geography 2019
  • Figure 29. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 31. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2019
  • Figure 33. Mylan N.V (United States) Revenue, Net Income and Gross profit
  • Figure 34. Mylan N.V (United States) Revenue: by Geography 2019
  • Figure 35. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Amgen Inc. (United States) Revenue: by Geography 2019
  • Figure 37. Zimmer Biomet (United States) Revenue, Net Income and Gross profit
  • Figure 38. Zimmer Biomet (United States) Revenue: by Geography 2019
  • Figure 39. Micromedic Technologies Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 40. Micromedic Technologies Ltd. (Israel) Revenue: by Geography 2019
  • Figure 41. Global Osteonecrosis: by Application USD Million (2020-2025)
  • Figure 42. Global Osteonecrosis: by Diagnoses Used USD Million (2020-2025)
  • Figure 43. Global Osteonecrosis: by Route of Administration USD Million (2020-2025)
  • Figure 44. Global Osteonecrosis: by Treatment Type USD Million (2020-2025)
  • Figure 45. South America Osteonecrosis Share (%), by Country
  • Figure 46. Asia Pacific Osteonecrosis Share (%), by Country
  • Figure 47. Europe Osteonecrosis Share (%), by Country
  • Figure 48. MEA Osteonecrosis Share (%), by Country
  • Figure 49. North America Osteonecrosis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bone Therapeutics SA (Belgium)
  • Enzo Biochem Inc. (United States)
  • Atnahs (United Kingdom)
  • Teva Pharmaceutical Industries (Israel)
  • Merck & Co. Inc. (United States)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Johnson & Johnson Services, Inc. (United States)
  • Mylan N.V (United States)
  • Amgen Inc. (United States)
  • Zimmer Biomet (United States)
  • Micromedic Technologies Ltd. (Israel)
Additional players considered in the study are as follows:
Exactech, Inc. (United States) , Medacta International (Switzerland) , Vericel Corporation (United States)
Select User Access Type

Key Highlights of Report


Apr 2020 206 Pages 56 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Osteonecrosis Market Quantitative research analysis
Global Osteonecrosis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Osteonecrosis Market Report?

Have a Query? Click Here

Other Related Reports

Influenza Treatment Comprehensive Study by Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, Others), Diagnostic Tests (Viral culture, Serology, Rapid antigen testing, Reverse tr...
$ 3750
Topical Use Acne Treatment Comprehensive Study by Type (Inflammatory Acne, Cystic Acne, Post-Surgical/Wound Acne), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Drug Type (...
$ 3750
Sacroiliitis Treatment Comprehensive Study by Type (Medication, Pain relievers, Muscle relaxants, TNF inhibitors, Joint Injections, Radiofrequency denervation, Electrical stimulation, Joint fusion), ...
$ 3450
Leishmaniasis Treatment Comprehensive Study by Application (Cutaneous leishmaniasis, Visceral leishmaniasis, Mucocutaneous leishmaniasis), Drug Type (Pentavalent antimonials (Sodium stibogluconate, S...
$ 3750
Phage Therapy Comprehensive Study by Application (Diagnostic, Antimicrobial Drug Discovery, Veterinary Medicines, Others), Route of Administration (Oral, Topical), Targeted Bacteria (Escherichia coli...
$ 3750
Respiratory Virus Infection Drugs Comprehensive Study by Type (Penicillin VK, Amoxicillin, Penicillin G benzathine, Cefadroxil, Erythromycin, Amoxicillin and clavulanate, Others), Disease Type (COVID...
$ 3750